A 61-year-old male patient was referred to the urology department of the University College London Hospitals (London, UK) in June, 2022, after experiencing left testicular and hip pain. Prior to the referral, his local general practitioner had prescribed antibiotics for suspected epididymo-orchitis. His symptoms improved and the patient was reassured. 1 month later, his pain relapsed and hip…

On March 31, 2023, US President Joe Biden’s administration appealed the ruling by Texas federal Judge Reed O’Connor on March 30, that said that some mandates in the Affordable Care Act (ACA; popularly called Obamacare), cannot be executed across the USA, including provisions that require insurance providers to cover a spectrum of preventive services at no cost to the patient. These services…

Access to childhood cancer medicines across east Africa is marked by gaps in availability that have implications for effective treatment delivery for a range of childhood cancers. Our findings provide detailed evidence of barriers to access to childhood cancer medicine at multiple points in the pharmaceutical value chain. These data could inform national and regional policy makers to optimise…

Belzutifan plus cabozantinib has promising antitumour activity in patients with pretreated clear cell renal cell carcinoma and our findings provide rationale for further randomised trials with belzutifan in combination with a VEGFR tyrosine-kinase inhibitor.

In The Lancet Oncology, Toni K Choueiri and colleagues1 report the findings from cohort 2 of a phase 2 trial of belzutifan plus cabozantinib in patients with renal cell carcinoma who had previously received an with one previous immune checkpoint inhibitor (28 [54%] of 52 patients enrolled) or immunotherapy and an anti-VEGF or anti-VEGFR tyrosine-kinase inhibitor (24 [46%]). The results were…